<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> regulation, although effective for <z:e sem="disease" ids="C0155765" disease_type="Disease or Syndrome" abbrv="">microangiopathy</z:e>, has not been shown to have unambiguous preventive effects on the occurrence of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:mp ids='MP_0002055'>diabetes</z:mp> show a characteristic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> (high <z:chebi fb="0" ids="17855">triglyceride</z:chebi> level, <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> level) </plain></SENT>
<SENT sid="2" pm="."><plain>Aggressive reduction of <z:chebi fb="4" ids="17855">triglycerides</z:chebi> might be an effective method to reduce the cardiovascular risk in these patients </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: A double-blind, placebo-controlled, randomized study to assess the effect of 30 weeks of administration of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 and 80 mg on plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels in 217 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and fasting <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels between 1.5 and 6.0 mmol/l </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Administration of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 and 80 mg resulted in significant reductions (25 and 35%, respectively) of plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels (both P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>The difference between 10 and 80 mg was not statistically significant (P &gt; 0.5) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> 10 mg provided significant reductions from baseline in total cholesterol (-30%, P &lt; 0.001), <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> (-40%, P &lt; 0.001), and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (-31%, P &lt; 0.001), and significantly increased <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> from baseline by 6% (P &lt; 0.005) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> 80 mg had a similar effect on <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi> (+5.2%, P &lt; 0.005) but significantly decreased total cholesterol (-40%, P &lt; 0.001), <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> (-52%, P &lt; 0.001), and <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> B (-40%, P &lt; 0.001) more than <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 mg (P &lt; 0.005) </plain></SENT>
<SENT sid="8" pm="."><plain>The side effects of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> 10 and 80 mg were similar and did not differ from the patients receiving placebo </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Administration of 10- and 80-mg doses of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> provides similar, significant reductions from baseline in <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>A higher dose of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> improves cholesterol-related parameters </plain></SENT>
<SENT sid="11" pm="."><plain>Both doses were well tolerated in this patient population </plain></SENT>
</text></document>